Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib in Metastatic Colorectal Cancer (COFRUQ)
NCT07124858Recruiting
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Mar 2026
- Primary completion
- Mar 2031
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of fruquintinib in colorectal cancer (CRC), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Overall Survival at 1 year. Started Mar 2026; status: recruiting.
02
Drugs
fruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07124858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07124858.